ProQR Therapeutics NV reports results for the quarter ended in June - Earnings Summary

ProQR Therapeutics NV

05/08/2021 17:50

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly adjusted
loss of 24 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 22 cents per share.
* Revenue fell 95.3% to €411.00 thousand from a year ago; 
analysts expected €239.43 thousand. 
* The mean earnings estimate of analysts had risen by
about 10.5% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* ProQR Therapeutics NV shares had fallen by 11.6% this
quarter and gained 41.9% so far this year.
* The company reported a quarterly loss of €15.89 million.
* Wall Street's median 12-month price target for ProQR
Therapeutics NV is $21.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 04:50 p.m.  ​All
figures in euros unless otherwise stated